Akiyo Yoshimura

1.7k total citations
67 papers, 1.2k citations indexed

About

Akiyo Yoshimura is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Akiyo Yoshimura has authored 67 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 23 papers in Cancer Research and 18 papers in Pathology and Forensic Medicine. Recurrent topics in Akiyo Yoshimura's work include Breast Cancer Treatment Studies (21 papers), Breast Lesions and Carcinomas (14 papers) and Cancer Treatment and Pharmacology (14 papers). Akiyo Yoshimura is often cited by papers focused on Breast Cancer Treatment Studies (21 papers), Breast Lesions and Carcinomas (14 papers) and Cancer Treatment and Pharmacology (14 papers). Akiyo Yoshimura collaborates with scholars based in Japan, United States and Nepal. Akiyo Yoshimura's co-authors include Hiroji Iwata, P Pritzl, Richard J. Johnson, Elaine W. Raines, Charles E. Alpers, J. Floege, Russell Ross, Masaya Hattori, Masataka Sawaki and Haruru Kotani and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Akiyo Yoshimura

60 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Akiyo Yoshimura Japan	18	508	377	352	279	177	67	1.2k
Shin‐ichi Tsuchiya Japan	19	304 0.6×	269 0.7×	287 0.8×	231 0.8×	213 1.2×	79	1.0k
Rajeev Mahimkar United States	15	323 0.6×	463 1.2×	372 1.1×	93 0.3×	49 0.3×	18	1.1k
Yong Mee Cho South Korea	22	449 0.9×	687 1.8×	288 0.8×	807 2.9×	93 0.5×	100	1.8k
Emma Tham Sweden	19	359 0.7×	470 1.2×	373 1.1×	138 0.5×	211 1.2×	59	1.2k
Yuki Hamano Japan	15	354 0.7×	814 2.2×	460 1.3×	188 0.7×	74 0.4×	27	2.0k
Bradley G. Somer United States	16	808 1.6×	412 1.1×	279 0.8×	304 1.1×	192 1.1×	45	1.3k
Tim H. Brümmendorf Germany	22	325 0.6×	753 2.0×	195 0.6×	219 0.8×	49 0.3×	86	1.6k
Hio Chung Kang South Korea	26	654 1.3×	1.1k 3.0×	312 0.9×	218 0.8×	292 1.6×	42	1.8k
Zhenhua Zhai China	14	484 1.0×	685 1.8×	356 1.0×	251 0.9×	45 0.3×	22	1.4k
Rachelle W. Johnson United States	26	1.0k 2.0×	907 2.4×	295 0.8×	198 0.7×	71 0.4×	55	1.8k

Countries citing papers authored by Akiyo Yoshimura

Since Specialization

Citations

This map shows the geographic impact of Akiyo Yoshimura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akiyo Yoshimura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akiyo Yoshimura more than expected).

Fields of papers citing papers by Akiyo Yoshimura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akiyo Yoshimura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akiyo Yoshimura. The network helps show where Akiyo Yoshimura may publish in the future.

Co-authorship network of co-authors of Akiyo Yoshimura

This figure shows the co-authorship network connecting the top 25 collaborators of Akiyo Yoshimura. A scholar is included among the top collaborators of Akiyo Yoshimura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akiyo Yoshimura. Akiyo Yoshimura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamashita, Toshinari, Shigehira Saji, Toshimi Takano, et al.. (2025). Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. Journal of Clinical Oncology. 43(11). 1302–1313. 5 indexed citations

Yamashita, Toshinari, Shigehira Saji, Toshimi Takano, et al.. (2024). Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).. Journal of Clinical Oncology. 42(16_suppl). 1007–1007. 2 indexed citations

Iwata, Hiroji, Yoichi Naito, Masaya Hattori, et al.. (2024). Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study. International Journal of Clinical Oncology. 30(1). 72–82. 4 indexed citations

Yoshimura, Akiyo, Masataka Sawaki, Masaya Hattori, et al.. (2023). Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy. Journal of Breast Cancer. 26(2). 117–117. 1 indexed citations

Iwata, Hiroji, Yoichi Naito, Akiyo Yoshimura, et al.. (2023). 58P Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study. Annals of Oncology. 34. S1488–S1489. 1 indexed citations

Kotani, Haruru, Masataka Sawaki, Masaya Hattori, et al.. (2023). Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report. SHILAP Revista de lepidopterología. 9(1). 112–112.

Endo, Yuka, Akiyo Yoshimura, Masataka Sawaki, et al.. (2022). Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use. Journal of Breast Cancer. 25(4). 296–296. 3 indexed citations

Ozaki, Yuri, Haruru Kotani, Yayoi Adachi, et al.. (2022). Satisfaction survey on a preoperative explanation method using three-dimensional breast imaging for breast cancer patients considering breast-conserving surgery. Surgery Today. 53(4). 476–482. 1 indexed citations

Kotani, Haruru, Mitsuo Terada, Makiko Mori, et al.. (2021). Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial. BMC Cancer. 21(1). 548–548. 13 indexed citations

10.

Yoshimura, Akiyo, Shiro Yokoyama, Hiroji Iwata, et al.. (2020). Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration. Journal of Human Genetics. 66(4). 379–387. 3 indexed citations

11.

Iwase, Madoka, Masaya Hattori, Masataka Sawaki, et al.. (2019). Presence of small residual malignant lesions in pathologic complete response after neo‐adjuvant chemotherapy in patients with breast cancer. The Breast Journal. 25(6). 1303–1305.

12.

Terada, Mitsuo, Akiyo Yoshimura, Masataka Sawaki, et al.. (2019). Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors. Breast Cancer Research and Treatment. 179(1). 91–100. 19 indexed citations

13.

Terada, Mitsuo, Masataka Sawaki, Masaya Hattori, et al.. (2019). A case of giant cell tumor of the breast, clinically suspected as malignant breast tumor. SHILAP Revista de lepidopterología. 5(1). 77–77. 8 indexed citations

14.

Hattori, Masaya, Hayao Nakanishi, Madoka Iwase, et al.. (2019). Circulating tumor cells detection in tumor draining vein of breast cancer patients. Scientific Reports. 9(1). 18195–18195. 21 indexed citations

15.

Hattori, Masaya, Hiroshi Ishiguro, Norikazu Masuda, et al.. (2017). Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study. Breast Cancer. 25(1). 108–117. 5 indexed citations

16.

Shimokawa, Tsuneo, Masahiro Seike, Chie Soeno, et al.. (2012). Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. British Journal of Cancer. 106(5). 867–875. 15 indexed citations

17.

Hashiguchi, Akihiro, Akiyo Yoshimura, Kazuhiko Maeda, et al.. (2012). Late-onset Charcot–Marie–Tooth disease 4F caused by periaxin gene mutation. Neurogenetics. 13(4). 359–365. 18 indexed citations

18.

Gemma, Akihiko, Rintaro Noro, Masahiro Seike, et al.. (2005). Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). British Journal of Cancer. 92(9). 1711–1719. 115 indexed citations

19.

Inui, Ken‐ichi, et al.. (1997). HMG-CoA Reductase Inhibitor Suppression of Glomerular Cell proliferation in Rats with Anti-Thy-1.1 Nephritis. Contributions to nephrology. 120. 153–159. 3 indexed citations

20.

Johnson, Richard J., Elaine W. Raines, J. Floege, et al.. (1992). Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor.. The Journal of Experimental Medicine. 175(5). 1413–1416. 308 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact